Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics Limited has announced the issuance of 480,769 unquoted equity securities in the form of Zero Exercise Price Options under an employee incentive scheme. This strategic move is likely aimed at retaining and motivating employees, potentially impacting the company’s operational efficiency and competitive positioning in the biotechnology sector.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on developing therapeutics for the treatment of cancer and fibrotic diseases. The company is engaged in advancing its pipeline of drug candidates to address unmet medical needs in these areas.
YTD Price Performance: 46.07%
Average Trading Volume: 1,786,766
Technical Sentiment Signal: Hold
Current Market Cap: A$66.7M
For an in-depth examination of ATX stock, go to TipRanks’ Overview page.